Keywords
Eligibility Determination ×
Carcinoma, Hepatocellular ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

160 Search results.

Eligibility Hepatocellular Carcinoma NCT01759901

- 10/7/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Vascular Inflow Occlusion in Open Liver Resection for Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01759901

Eligibility Probiotics before Liver Resection in Liver Disease NCT02021253

- 10/7/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Influence of Probiotics Administration Before Liver Resection in Liver Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02021253

Eligibility Localized Non-Resectable Adult Hepatocellular Carcinoma NCT01910909

- 7/2/20 - 1 form, 2 itemgroups, 24 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01910909

Eligibility Liver Carcinoma NCT01482442

- 6/29/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01482442

Eligibility Hepatocellular Carcinoma NCT01281683

- 6/12/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01281683

Eligibility Hepatocellular Carcinoma NCT02182687

- 6/6/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT02182687

Eligibility Hepatocellular Carcinoma NCT01968629

- 6/6/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
24hr Imaging Of HCC After EOVIST; ODM derived from: https://clinicaltrials.gov/show/NCT01968629

Eligibility Hepatocellular Carcinoma NCT02267213

- 6/6/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02267213

Eligibility Hepatocellular Carcinoma NCT00862082

- 6/5/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC); ODM derived from: https://clinicaltrials.gov/show/NCT00862082

Eligibility Hepatocellular Carcinoma NCT00669136

- 6/5/20 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00669136

Eligibility Hepatocellular Carcinoma NCT01686880

- 6/5/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver; ODM derived from: https://clinicaltrials.gov/show/NCT01686880

Eligibility Hepatocellular Carcinoma NCT00906373

- 6/5/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver; ODM derived from: https://clinicaltrials.gov/show/NCT00906373